Pomanda estimates the enterprise value of ONCOLOGY SYSTEMS LIMITED at £1.7m based on a Turnover of £3.8m and 0.44x industry multiple (adjusted for size and gross margin).
oncology systems limitedEstimated Valuation
£2.2m
Pomanda estimates the enterprise value of ONCOLOGY SYSTEMS LIMITED at £2.2m based on an EBITDA of £458.1k and a 4.89x industry multiple (adjusted for size and gross margin).
oncology systems limitedEstimated Valuation
£3.2m
Pomanda estimates the enterprise value of ONCOLOGY SYSTEMS LIMITED at £3.2m based on Net Assets of £1.6m and 1.99x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Oncology Systems LimitedOverview
Oncology Systems Limited is a live company located in shrewsbury, SY1 3GZ with a Companies House number of 03748527. It operates in the retail sale of medical and orthopaedic goods in specialised stores (not incl. hearing aids) n.e.c. sector, SIC Code 47749. Founded in April 1999, it's largest shareholder is
julie mary mead
with a 48.7% stake. Oncology Systems Limited is a mature,
small sized company, Pomanda has estimated its turnover at
£3.8m with
healthy
growth in recent years.
Pomanda's financial health check has awarded Oncology Systems Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 3 areas for improvement. Company Health Check FAQs
Health Rating5out of 5
4 Strong
5 Regular
3 Weak
Size
annual sales of £3.8m, make it smaller than the average company (£13.6m)
£3.8m - Oncology Systems Limited
£13.6m - Industry AVG
Growth
3 year (CAGR) sales growth of 7%, show it is growing at a similar rate (7.5%)
7% - Oncology Systems Limited
7.5% - Industry AVG
Production
with a gross margin of 37.7%, this company has a comparable cost of product (37.7%)
37.7% - Oncology Systems Limited
37.7% - Industry AVG
Profitability
an operating margin of 9.8% make it more profitable than the average company (5.2%)
9.8% - Oncology Systems Limited
5.2% - Industry AVG
Employees
with 13 employees, this is below the industry average (50)
13 - Oncology Systems Limited
50 - Industry AVG
Pay Structure
on an average salary of £62.8k, the company has an equivalent pay structure (£62.8k)
£62.8k - Oncology Systems Limited
£62.8k - Industry AVG
Efficiency
resulting in sales per employee of £294.3k, this is equally as efficient (£287.5k)
£294.3k - Oncology Systems Limited
£287.5k - Industry AVG
Debtor Days
it gets paid by customers after 87 days, this is later than average (50 days)
87 days - Oncology Systems Limited
50 days - Industry AVG
Creditor Days
its suppliers are paid after 41 days, this is close to average (40 days)
41 days - Oncology Systems Limited
40 days - Industry AVG
Stock Days
it holds stock equivalent to 33 days, this is less than average (67 days)
33 days - Oncology Systems Limited
67 days - Industry AVG
Cash Balance
has cash to cover current liabilities
for 13 weeks, this is more cash available to meet short term requirements (10 weeks)
13 weeks - Oncology Systems Limited
10 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 40.7%, this is a lower level of debt than the average (48.2%)
40.7% - Oncology Systems Limited
48.2% - Industry AVG
ONCOLOGY SYSTEMS LIMITED financials
EXPORT
Oncology Systems Limited's latest turnover from April 2024 is estimated at £3.8 million and the company has net assets of £1.6 million. According to their latest financial statements, Oncology Systems Limited has 13 employees and maintains cash reserves of £277.8 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Apr 2024
Apr 2023
Apr 2022
Apr 2021
Apr 2020
Apr 2019
Apr 2018
Apr 2017
Apr 2016
Apr 2015
Apr 2014
Apr 2013
Apr 2012
Apr 2011
Apr 2010
Turnover
3,826,145
3,712,405
2,927,421
3,112,974
6,757,528
4,857,730
3,740,307
4,974,070
4,352,001
5,533,254
9,224,984
8,603,026
9,825,531
9,360,065
9,038,926
Other Income Or Grants
Cost Of Sales
2,384,499
2,237,892
1,797,233
2,040,656
4,519,964
3,174,062
2,391,509
3,063,451
2,567,064
3,272,871
5,837,898
5,496,695
5,610,274
5,464,098
5,187,129
Gross Profit
1,441,646
1,474,513
1,130,188
1,072,318
2,237,564
1,683,668
1,348,798
1,910,619
1,784,937
2,260,382
3,387,085
3,106,332
4,215,257
3,895,967
3,851,797
Admin Expenses
1,068,408
1,697,880
1,613,198
1,110,041
2,248,481
1,711,098
1,390,790
1,555,313
1,653,256
2,496,674
3,398,403
3,113,515
2,926,054
2,070,368
2,170,705
Operating Profit
373,238
-223,367
-483,010
-37,723
-10,917
-27,430
-41,992
355,306
131,681
-236,292
-11,318
-7,183
1,289,203
1,825,599
1,681,092
Interest Payable
60
60,066
59,130
Interest Receivable
28,612
53,956
12,745
1,608
1,567
13,028
8,631
2,977
4,280
6,274
12,088
13,865
Pre-Tax Profit
401,849
-169,411
-470,265
-36,115
-9,350
-14,402
-33,361
358,283
135,961
-230,018
771
6,682
1,292,584
1,765,533
1,621,962
Tax
-100,462
-68,074
-27,192
-162
-1,537
-230,785
-471,758
-428,073
Profit After Tax
301,387
-169,411
-470,265
-36,115
-9,350
-14,402
-33,361
290,209
108,769
-230,018
609
5,145
1,061,799
1,293,775
1,193,889
Dividends Paid
780,000
1,250,001
1,080,000
Retained Profit
301,387
-169,411
-470,265
-36,115
-9,350
-14,402
-33,361
290,209
108,769
-230,018
609
5,145
281,799
43,774
113,889
Employee Costs
816,457
1,003,139
740,122
836,558
930,326
789,108
842,433
765,615
868,322
911,400
1,481,060
1,413,662
1,256,551
696,304
633,142
Number Of Employees
13
17
13
14
16
14
15
15
18
24
35
31
13
14
13
EBITDA*
458,075
-134,058
-375,618
67,689
98,546
83,677
59,034
824,918
426,232
-54,263
360,824
274,971
1,475,875
1,963,906
1,794,706
* Earnings Before Interest, Tax, Depreciation and Amortisation
Apr 2024
Apr 2023
Apr 2022
Apr 2021
Apr 2020
Apr 2019
Apr 2018
Apr 2017
Apr 2016
Apr 2015
Apr 2014
Apr 2013
Apr 2012
Apr 2011
Apr 2010
Tangible Assets
316,370
326,580
322,757
318,881
333,502
972,605
960,783
722,741
728,384
612,158
622,559
622,276
631,304
628,125
634,966
Intangible Assets
122,076
169,254
183,476
210,178
231,013
250,554
278,995
233,576
526,006
627,832
607,214
749,431
662,701
443,245
347,567
Investments & Other
767,000
767,000
657,500
657,500
646,907
Debtors (Due After 1 year)
Total Fixed Assets
1,205,446
1,262,834
1,163,733
1,186,559
1,211,422
1,223,159
1,239,778
956,317
1,254,390
1,239,990
1,229,773
1,371,707
1,294,005
1,071,370
982,533
Stock & work in progress
215,681
196,309
218,292
145,605
155,021
105,378
97,254
142,166
159,605
147,549
119,150
103,432
87,091
96,115
123,174
Trade Debtors
918,406
581,313
611,928
470,333
1,712,697
1,238,736
842,007
1,060,545
1,033,292
947,252
1,313,030
844,065
1,369,777
1,078,260
1,070,383
Group Debtors
Misc Debtors
87,688
216,225
48,577
11,357
11,145
29,829
24,033
155,368
65,120
41,542
107,743
Cash
277,839
812,123
1,726,975
1,671,796
1,544,509
1,590,263
1,883,952
1,568,587
812,889
899,286
1,610,285
3,225,091
2,320,709
2,306,897
1,356,904
misc current assets
total current assets
1,499,614
1,805,970
2,605,772
2,299,091
3,423,372
2,964,206
2,847,246
2,926,666
2,070,906
1,994,087
3,042,465
4,172,588
3,819,119
3,589,015
2,550,461
total assets
2,705,060
3,068,804
3,769,505
3,485,650
4,634,794
4,187,365
4,087,024
3,882,983
3,325,296
3,234,077
4,272,238
5,544,295
5,113,124
4,660,385
3,532,994
Bank overdraft
Bank loan
Trade Creditors
271,130
410,102
206,122
186,908
743,137
496,482
481,400
816,538
336,882
1,643,482
2,441,011
3,673,596
465,491
538,890
132,144
Group/Directors Accounts
8,824
495,608
1,177,225
490,440
830,172
587,704
306,758
574
347,439
1,627,765
1,398,824
556,056
other short term finances
hp & lease commitments
other current liabilities
769,661
789,093
951,817
905,451
1,100,942
1,129,573
1,307,867
1,006,746
853,118
1,166,480
1,195,335
1,387,504
total current liabilities
1,049,615
1,694,803
2,335,164
1,582,799
2,674,251
2,213,759
2,096,025
1,823,858
1,537,439
1,643,482
2,441,011
3,673,596
3,259,736
3,133,049
2,075,704
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
52,139
63,520
57,607
55,852
53,882
57,595
60,586
95,351
114,292
140,799
151,413
191,494
179,328
137,575
111,303
total long term liabilities
52,139
63,520
57,607
55,852
53,882
57,595
60,586
95,351
114,292
140,799
151,413
191,494
179,328
137,575
111,303
total liabilities
1,101,754
1,758,323
2,392,771
1,638,651
2,728,133
2,271,354
2,156,611
1,919,209
1,651,731
1,784,281
2,592,424
3,865,090
3,439,064
3,270,624
2,187,007
net assets
1,603,306
1,310,481
1,376,734
1,846,999
1,906,661
1,916,011
1,930,413
1,963,774
1,673,565
1,449,796
1,679,814
1,679,205
1,674,060
1,389,761
1,345,987
total shareholders funds
1,603,306
1,310,481
1,376,734
1,846,999
1,906,661
1,916,011
1,930,413
1,963,774
1,673,565
1,449,796
1,679,814
1,679,205
1,674,060
1,389,761
1,345,987
Apr 2024
Apr 2023
Apr 2022
Apr 2021
Apr 2020
Apr 2019
Apr 2018
Apr 2017
Apr 2016
Apr 2015
Apr 2014
Apr 2013
Apr 2012
Apr 2011
Apr 2010
Operating Activities
Operating Profit
373,238
-223,367
-483,010
-37,723
-10,917
-27,430
-41,992
355,306
131,681
-236,292
-11,318
-7,183
1,289,203
1,825,599
1,681,092
Depreciation
13,787
14,362
13,265
8,789
9,660
6,351
2,300
5,643
6,755
10,401
15,550
14,227
16,221
21,082
37,195
Amortisation
71,050
74,947
94,127
96,623
99,803
104,756
98,726
463,969
287,796
171,628
356,592
267,927
170,451
117,225
76,419
Tax
-100,462
-68,074
-27,192
-162
-1,537
-230,785
-471,758
-428,073
Stock
19,372
-21,983
72,687
-9,416
49,643
8,124
-44,912
-17,439
12,056
28,399
15,718
16,341
-9,024
-27,059
123,174
Debtors
208,556
137,033
178,815
-1,242,152
455,277
402,525
-349,873
117,501
151,160
-365,778
468,965
-567,254
225,316
115,620
1,070,383
Creditors
-138,972
203,980
19,214
-556,229
246,655
15,082
-335,138
479,656
-1,306,600
-797,529
-1,232,585
3,208,105
-73,399
406,746
132,144
Accruals and Deferred Income
-19,432
-162,724
46,366
-195,491
-28,631
-178,294
301,121
153,628
853,118
-1,166,480
-28,855
-192,169
1,387,504
Deferred Taxes & Provisions
-11,381
5,913
1,755
1,970
-3,713
-2,991
-34,765
-18,941
-26,507
-10,614
-40,081
12,166
41,753
26,272
111,303
Cash flow from operations
-40,100
-201,939
-559,785
569,507
-192,063
-493,175
385,037
1,271,125
-244,165
-525,027
-1,396,687
2,878,138
968,297
1,644,436
1,804,027
Investing Activities
capital expenditure
-27,449
-78,910
-84,566
-69,956
549,181
-94,488
-384,487
-171,539
-308,951
-192,246
-230,208
-359,856
-410,171
-227,144
-181,622
Change in Investments
109,500
10,593
646,907
cash flow from investments
-27,449
-188,410
-84,566
-80,549
-97,726
-94,488
-384,487
-171,539
-308,951
-192,246
-230,208
-359,856
-410,171
-227,144
-181,622
Financing Activities
Bank loans
Group/Directors Accounts
-486,784
-681,617
686,785
-339,732
242,468
280,946
306,184
-346,865
347,439
-1,627,765
228,941
842,768
556,056
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
-8,562
103,158
-23,547
115,000
2,500
1,232,098
interest
28,612
53,956
12,745
1,608
1,567
13,028
8,631
2,977
4,280
6,274
12,088
13,865
-60
-60,066
-59,130
cash flow from financing
-466,734
-524,503
699,530
-361,671
244,035
293,974
314,815
-343,888
466,719
6,274
12,088
-1,613,900
231,381
782,702
1,729,024
cash and cash equivalents
cash
-534,284
-914,852
55,179
127,287
-45,754
-293,689
315,365
755,698
-86,397
-710,999
-1,614,806
904,382
13,812
949,993
1,356,904
overdraft
change in cash
-534,284
-914,852
55,179
127,287
-45,754
-293,689
315,365
755,698
-86,397
-710,999
-1,614,806
904,382
13,812
949,993
1,356,904
oncology systems limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for oncology systems limited. Get real-time insights into oncology systems limited's credit score, group structure and payment trends.
Perform a competitor analysis for oncology systems limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other small companies, companies in SY1 area or any other competitors across 12 key performance metrics.
oncology systems limited Ownership
ONCOLOGY SYSTEMS LIMITED group structure
Oncology Systems Limited has no subsidiary companies.
Ultimate parent company
ONCOLOGY SYSTEMS LIMITED
03748527
ONCOLOGY SYSTEMS LIMITED Shareholders
The largest shareholders in Oncology Systems Limited include Julie Mary Mead and Carl Robert Pavey.
julie mary mead
48.68%
carl robert pavey
42.48%
alice rose pavey
6.2%
carl douglas walker
2.63%
oncology systems limited directors
Oncology Systems Limited currently has 2 directors.
The longest serving directors include
Mr Carl Pavey (Apr 1999) and
Miss Alice Pavey (Mar 2023).
47749 - Retail sale of medical and orthopaedic goods (other than hearing aids) n.e.c., in specialised stores
incorporation date
April 1999
age
26
incorporated
UK
ultimate parent company
None
accounts
Total Exemption Full
last accounts submitted
April 2024
previous names
N/A
accountant
HARVEY TELFORD & BATES
auditor
-
address
14 longbow professional centre, longbow close, shrewsbury, shropshire, SY1 3GZ
Bank
-
Legal Advisor
-
oncology systems limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to oncology systems limited.
oncology systems limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ONCOLOGY SYSTEMS LIMITED. This can take several minutes, an email will notify you when this has completed.
oncology systems limitedCompanies House Filings - See Documents
